Group 1 - The core point of the article is that Zhend Medical (SH 603301) held its fourth fifth board meeting on December 15, 2025, to discuss the proposal for the 2026 first extraordinary shareholders' meeting [1] - Zhend Medical's revenue composition for the first half of 2025 was entirely from medical dressings, accounting for 100.0% [2] - As of the report, Zhend Medical's market capitalization was 17.6 billion yuan [2] Group 2 - The article mentions a controversy surrounding a product called "Tongyan Needle," which reportedly generated 300 million yuan in annual sales, with concerns raised about the legitimacy of several related parties [2] - There are allegations that the Qian siblings have nearly "emptied" Jiangsu Wuzhong, leading to the company's impending delisting [2]

振德医疗用品股份有限公司 章程 （修订稿） | | | | | | | 第三节 会计师事务所的聘任 . | | --- | | 第八章 通知和公告 | | 第一节 通知 … | | 第二节 公 告 | | 第九章 合并、分立、增资、减资、解散和清算 | | 第一节 合并、分立、增资和减资 | | 第二节 解散和清算 | | 第十章 修改章程 . | | 第十一章 | 振德医疗用品股份有限公司 章程 （修订稿） 第一章 总则 第一条 为维护振德医疗用品股份有限公司（以下简称"公司"或"本公 司"）、股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）等其他有关规定，制订本章程。 第二条 公司系依照《公司法》等有关法律法规的规定，由原绍兴振德医用 敷料有限公司整体变更发起设立的股份有限公司。公司在浙江省市场监督管理局 注册登记，取得营业执照，统一社会信用代码：91330600609661634M。 第三条 公司于 2018 年 3 月 12 日经中国证券监督管理委员会核准，首次向 社会公众发行人民币普通股 ...

二、修改《公司章程》 鉴于公司住所变更，根据相关法律、法规规定，拟对《公司章程》 进行修改，修改情况如下： | 序号 | 修改前 | 修改后 | | | --- | --- | --- | --- | | | 第五条 公司住所：浙江省绍兴市 | 第五条 | 公司住所：浙江省绍兴市越 | | 1 | 越城区皋埠街道皋北工业区，邮编： | 城区皋埠街道香积路 | 55 号，邮编：312035。 | | | 312035。 | | | 证券代码：603301 证券简称：振德医疗 公告编号：2025-045 振德医疗用品股份有限公司 关于变更公司住所及修改《公司章程》并办理工商 变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日召开第四届董事会第五次会议，审议通过了《关于变更公司 住所及修改<公司章程>并办理工商变更登记的议案》，现将有关事项 公告如下： 一、变更公司住所 根据公司经营管理需要并结合实际情况，公司住所拟由"浙江省 绍兴市越城区 ...

证券代码：603301 证券简称：振德医疗 公告编号：2025-044 振德医疗用品股份有限公司 关于公司第二期员工持股计划第三个解锁期解锁条件 未达成暨锁定期届满的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日召开了第四届董事会第五次会议审议通过《关于公司第二期 员工持股计划第三个解锁期解锁条件未达成情况的议案》，具体情况 如下： 起 12 个月后开始分三期解锁，锁定期最长 36 个月，具体如下： 第一批解锁时点：自公司公告最后一笔标的股票过户至本员工持 股计划名下之日起算满 12 个月。 第二批解锁时点：自公司公告最后一笔标的股票过户至本员工持 股计划名下之日起算满 24 个月。 一、第二期员工持股计划的基本情况 公司分别于 2022 年 9 月 30 日、2022 年 10 月 20 日召开第三届 董事会第四次会议和 2022 年第二次临时股东大会，审议通过了《关 于<公司第二期员工持股计划（草案）>及其摘要的议案》等相关议案， 同意 ...

证券代码：603301 证券简称：振德医疗 公告编号：2025-046 振德医疗用品股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 召开的日期时间：2026 年 1 月 5 日 14 点 00 分 召开地点：浙江省绍兴市越城区皋埠街道香积路 55 号振德医疗用品股份有 限公司会议室 (五) 网络投票的系统、起止日期和投票时间。 股东会召开日期：2026年1月5日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 5 日 至2026 年 1 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当 ...

证券代码：603301 证券简称：振德医疗 公告编号：2025-043 振德医疗用品股份有限公司 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案已经公司第四届董事会薪酬与考核委员会第一次会议、审 计委员会第五次会议审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、审议通过《关于变更公司住所及修改<公司章程>并办理工商 变更登记的议案》，董事会同意变更公司住所及修改《公司章程》事 项，并提请股东会授权公司经营层办理变更公司住所及修改《公司章 程》工商变更登记手续（最终以市场监督管理局核准的内容为准）。 《公司章程》修改情况如下： | 序号 | 修改前 | 修改后 | | --- | --- | --- | | | 第五条 公司住所：浙江省绍兴市 | 第五条 公司住所：浙江省绍兴市越 | | 1 | 越城区皋埠街道皋北工业区，邮编： | 城区皋埠街道香积路 55 号，邮编： | | | 312035。 | 312035 ...

Core Insights - The global adhesive bandage market is projected to reach a sales value of $2.33 billion in 2024 and is expected to grow to $3.45 billion by 2031, with a compound annual growth rate (CAGR) of 6.15% [3] - The market expansion is driven by increasing consumer health awareness, the proliferation of home healthcare, and continuous innovation in functional adhesive bandage products [3] Market Overview - The European market is currently the largest consumer of adhesive bandages, accounting for 32.60% of global consumption in 2024, followed by North America at 30.19% and China at 11.06% [3] - China's market is expected to grow significantly, reaching $445 million by 2031, with its global market share increasing to 12.89% due to rising consumer spending and healthcare improvements [3] - Southeast Asia is anticipated to be the fastest-growing emerging market, with a CAGR of 9.75% from 2025 to 2031 [3] Production Insights - China and North America are the two major manufacturing hubs for adhesive bandages, with China expected to account for 64.23% of global production in 2024 [4] - By 2031, China's production share is projected to increase to 66.84%, indicating a shift from a manufacturing center to a hub for brand output and technological innovation [4] Product Structure - Hydrocolloid adhesive bandages dominate the global market, expected to reach a market share of 56.55% by 2031, driven by their superior breathability and moisture retention properties [4] - The trend towards high-end products is evident, particularly in the European and North American markets [4] Sales Channels - Online sales are becoming a significant growth driver, with an estimated market share of 8.78% in 2024 and a projected CAGR of 20.46% in the coming years [4] - The development of e-commerce platforms enhances consumer convenience and provides brands with greater market visibility and data-driven marketing capabilities [4] Competitive Landscape - The global adhesive bandage market is characterized by high concentration, with Kenvue holding approximately 36.94% of the market share in 2024 [7] - Major competitors include Beiersdorf, 3M, and Medline Industries, collectively holding about 36.81% of the market [7] - Future growth areas include functional adhesive bandages, children's bandages, and sports protection bandages [7] Industry Drivers - The rise in health consciousness among consumers is leading to increased demand for adhesive bandages in daily life [8] - Technological advancements in materials and processes are enhancing product performance and comfort, thereby boosting industry growth [8] - Regulatory standards in the medical device sector are influencing industry development, focusing on product quality, safety, and environmental considerations [8] Challenges - The adhesive bandage industry faces intense price competition due to low entry barriers, leading to compressed profit margins [10] - Brand homogenization is prevalent, with many products lacking significant differentiation, which can result in price wars [10] - Consumer loyalty is low, as adhesive bandages are low-cost items, making consumers more susceptible to price and promotional influences [10] - Stricter regulations in the medical device sector pose risks for companies that fail to comply with quality and safety standards [10]

Core Viewpoint - The stock of Zhendemedical (603301) experienced a decline of 2.28% on December 10, 2025, closing at 72.37 yuan, with significant net outflows from major funds and a mixed performance from retail investors [1][2]. Group 1: Stock Performance and Trading Data - On December 10, 2025, Zhendemedical's trading volume was 70,200 hands, with a total transaction amount of 504 million yuan [1]. - The net outflow of major funds was 31.21 million yuan, accounting for 6.19% of the total transaction amount, while retail investors saw a net inflow of 17.17 million yuan, representing 3.41% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in net fund flows, with a notable net inflow of 106 million yuan on December 9, 2025, followed by a significant outflow on December 10 [2]. Group 2: Financing and Margin Trading Data - On December 10, 2025, the financing balance was 1.45 billion yuan, with a net repayment of 11.43 million yuan [3]. - The margin trading data indicates a total margin balance of 1.45 billion yuan, with a short selling of 600 shares and a remaining short position of 14,500 shares [3]. Group 3: Company Financials and Industry Comparison - For the first three quarters of 2025, Zhendemedical reported a main business revenue of 3.184 billion yuan, a year-on-year increase of 1.88%, but a net profit of 203 million yuan, down 33.91% year-on-year [5]. - The company's gross profit margin stands at 33.93%, significantly lower than the industry average of 51.22%, ranking 97th out of 124 in the medical device industry [5]. - Zhendemedical's total market capitalization is 19.239 billion yuan, with a price-to-earnings ratio of 71.01, which is higher than the industry average of 62.74 [5].

Core Viewpoint - Zhendemedical (603301.SH) reported a closing price of 69.20 yuan, with a decline of 5.99% [1] Group 1: Company Performance - Huachuang Securities analysts noted that Zhendemedical's profit growth is temporarily pressured by a high base, but acquisitions are opening new growth opportunities [1] - The analysts maintained a "strong buy" rating for Zhendemedical [1]

Market Overview - On December 4, A-shares showed mixed performance with the three major indices fluctuating. The total market turnover was 1.56 trillion yuan, a decrease of over 120 billion yuan compared to the previous trading day. More than 1,400 stocks closed higher, with 40 stocks hitting the daily limit up [1]. Sector Performance - The electric motor concept led the gains, with Sanxie Electric rising over 17%. Other sectors such as reducers, state-owned fund holdings, and aviation engines also saw increases. In contrast, sectors like Hainan, tourism and hotels, and dairy products experienced the largest declines [1]. Institutional Ratings - Five stocks received buy ratings from institutions today, including Zhend Medical, New Town Holdings, and Shanxi Fenjiu. The average decline for these stocks was 1.37%, underperforming the Shanghai Composite Index. The largest declines were seen in Shanxi Fenjiu (3.42%), Zhend Medical (2.50%), and New Town Holdings (1.42%) [1]. Institutional Buying and Selling - In the Dragon and Tiger list, 15 stocks were net bought, with 11 stocks net sold. Nine stocks had net purchases exceeding 10 million yuan, led by Heertai with a net buy of 330 million yuan. The largest net sell was in Aerospace Development, with a net sell of 364 million yuan [4][5]. Northbound Capital Flow - Northbound funds saw net purchases in 10 stocks, with Heertai leading at 188 million yuan. Conversely, nine stocks experienced net selling, with Tongyu Communications facing the highest net sell of 146 million yuan [6][7]. Important Announcements - ST Xianhe announced the removal of risk warnings and a name change to "Xianhe Environmental Protection." Zhongbai Group closed 30 large warehouse stores, expecting a loss of 180 million yuan. China Petroleum signed contracts worth 40 billion yuan to acquire 100% equity in three gas storage companies [8].